DeBORAH BARNES, Magistrate Judge.
Defendant and counterclaimant, Dr. Zhixiang Hu, Ph.D., is proceeding in this action pro se. (ECF No. 68.) Accordingly, this action has been referred to the undersigned pursuant to Local Rule 302(c)(21) and 28 U.S.C. § 636(b)(1). Pending before the undersigned are defendant's motion to disqualify plaintiff's counsel, plaintiff's partial motion to dismiss and strike defendant's amended counterclaim, and motions to dismiss for lack of personal jurisdiction and insufficient service of process filed by counter-defendants CSPC Pharmaceutical Group Limited, Yingui Li, Jinxu Wang, Jumin Sun, and Dongchen Cai.
For the reasons explained below, defendant's motion to disqualify is denied, the motions to dismiss filed by plaintiff and counter-defendants are granted, and defendant is granted leave to file a second amended counterclaim and effect proper service.
Plaintiff CSPC Dophen Corporation ("CSPC Dophen") commenced this action on September 11, 2017. (ECF No. 1.) Plaintiff filed an amended complaint on October 13, 2017. (ECF No. 14.) According to the amended complaint, plaintiff is a pharmaceutical and development company based in Sacramento, California. (Am. Compl. (ECF No. 14) at 2.
The amended complaint alleges that on April 24, 2014, defendant incorporated a competing entity named Dophen Biomed, Inc., with the same address as CSPC Dophen, and took trade secrets and personal property belonging to plaintiff. (
On May 30, 2018, plaintiff filed a motion to dismiss and a motion to strike defendant's amended counterclaim. (ECF No. 70.) Defendant filed an opposition on June 14, 2018. (ECF No. 74.) On June 22, 2018, plaintiff filed a reply. (ECF No. 79.) On June 26, 2018, the undersigned took the motion to dismiss under submission. (ECF No. 81.)
On July 13, 2018, defendant filed a motion to disqualify plaintiff's counsel. (ECF No. 84.) Plaintiff filed an opposition on July 27, 2018. (ECF No. 87.) Defendant filed a reply on August 3, 2018. (ECF No. 91.) On August 6, 2018, the undersigned took the motion to disqualify under submission. (ECF No. 92.)
On August 13, 2018, counter-defendant CSPC Pharmaceutical Group Limited filed a motion to dismiss Dr. Hu's counterclaims for lack of personal jurisdiction and insufficient service of process. (ECF No. 95.) Counter-defendants Yingui Li, Jinxu Wang, Jumin Sun, and Dongchen Cai filed the same motion on August 16, 2018. (ECF No. 96.) Counterclaimant Dr. Hu filed oppositions on August 31, 2018. (ECF Nos. 97 & 99.) Counter-defendants filed replies on September 7, 2018. (ECF Nos. 100 & 101.) On September 10, 2018, the undersigned took counter-defendants' motions to dismiss under submission. (ECF No. 102.)
Defendant's motion argues that the law firm representing plaintiff—Morrison & Foerster LLP—previously represented plaintiff, "obtained confidential information" as a result of that representation, and now "stands in the middle of the dispute" between the firm's current client and a former client. (Def.'s Mot. Disq. (ECF No. 84-1) at 2.) Defendant contends that attorneys with Morrison & Foerster "have become witnesses in this current litigation[.]" (
The court applies "state law in determining matters of disqualification[.]"
Defendant's motion relies on California Rule of Professional Conduct 3-310(E), which provides that "[a] member shall not, without the informed written consent of the client or former client, accept employment adverse to the client or former client where, by reason of the representation of the client or former client, the member has obtained confidential information material to the employment." In this regard, "[w]here an attorney successively represents clients with adverse interests, and where the subjects of the two representations are substantially related, the need to protect the first client's confidential information requires that the attorney be disqualified from the second representation."
Here, attorneys with Morrison & Foerster never represented the defendant, thus the defendant is not a former client of Morrison & Foerster. Defendant's motion argues that "[o]n March 29, 2013, Morrison Foerster sent [defendant] Dr. Hu an engagement letter outlining the terms of Morrison Foerster's performance of legal services on behalf of Dophen Biomedical and [defendant] Dr. Hu." (Def.'s Mot. Disq. (ECF No. 84-1) at 4.) The March 29, 2013 engagement letter, however, states only that "Morrision & Foerster LLP . . . has been engaged to represent Dophen Biomedical[.]"
Although Dr. Hu signed the engagement letter, he did so as "Director" so that the engagement could be "APPROVED AND AGREED TO" by "DOPHEN BIOMEDICAL." (
Moreover, the scope of Morrison & Foerster's engagement concerned only "advice on patent prosecution." (
Accordingly, for the reasons stated above, defendant's motion to disqualify plaintiff's counsel is denied.
As noted above, on December 6, 2017, defendant filed an amended counterclaim. (ECF No. 39.) The amended counterclaim contains eleven discrete counterclaims. (
The purpose of a motion to dismiss pursuant to Rule 12(b)(6) is to test the legal sufficiency of the complaint.
In determining whether a counterclaim states a claim on which relief may be granted, the court accepts as true the allegations in the counterclaim and construes the allegations in the light most favorable to the nonmoving party.
In ruling on a motion to dismiss brought pursuant to Rule 12(b)(6), the court is permitted to consider material which is properly submitted as part of the counterclaim, documents that are not physically attached if their authenticity is not contested and the defendant's counterclaim necessarily relies on them, and matters of public record.
A motion to strike pursuant to Rule 12(f) allows a court to strike "from any pleading any insufficient defense or any redundant, immaterial, impertinent, or scandalous matter." Fed. R. Civ. P. 12(f). "[T]he function of a 12(f) motion to strike is to avoid the expenditure of time and money that must arise from litigating spurious issues by dispensing with those issues prior to trial[.]"
A motion to strike is well-taken when "it is clear that the matter to be stricken could have no possible bearing on the subject matter of litigation."
Ultimately, whether to grant a motion to strike applying these standards lies within the sound discretion of the district court.
Plaintiff seeks dismissal of defendant's third amended counterclaim for defamation on the grounds that defendant "has failed to plead nearly all the required elements[.]" (Pl.'s MTD (ECF No. 70) at 21.) In order to allege a prima facie claim for defamation, a party must allege facts that establish the existence of "(a) a publication that is (b) false, (c) defamatory, and (d) unprivileged, and that (e) has a natural tendency to injure or that causes special damage."
Here, defendant's counterclaim alleges simply that "at various times" plaintiff, plaintiff's employees, and plaintiff's representatives defamed defendant "by publishing statements concerning [defendant's] alleged theft of CSPC funds and assets, among other false and defamatory statements." (Def.'s Am. CC (ECF No. 39) at 11-12.) Defendant's counterclaim lacks any further specificity. Thus, it is entirely unclear: (1) what allegedly defamatory statement was made; (2) when it was made; (3) to whom it was made; and (4) that the statement had a natural tendency to injure of cause special damages.
Accordingly, plaintiff's motion to dismiss is granted as to this counterclaim. For the reasons explained below, defendant is granted leave to amend this counterclaim.
Plaintiff also seeks dismissal of defendant's fifth amended counterclaim, for conversion, and eleventh amended counterclaim, for money had and received. Plaintiff argues that these claims "are based on the same facts" and "cannot state a cause of action against CSPC Dophen, as opposed to [counter-defendant] CSPC Limited." (Pl.'s MTD (ECF No. 70) at 11-12.)
"To state a [counterclaim] for conversion under California law, a [defendant] must establish: (1) the [defendant's] ownership or right to possession of a certain piece of property; (2) the [plaintiff's] conversion of the property by a wrongful act or disposition of property rights; and (3) damages."
Here, Dr. Hu's counterclaims allege that "[o]n or about September 17, 2013," Dr. Hu wired money "to a bank specified by [counter-defendant] Jumin Sun, with the intent of purchasing CSPC Limited Stock." (Def.'s Am. CC (ECF No. 39) at 14, 22.) Jumin Sun informed Dr. Hu "that the funds had been received by CSPC Limited" but, nevertheless, CSPC Limited "refused to acknowledge [Dr. Hu's] ownership interest in CSPC Limtied[.]" (
However, according to the amended counterclaim, counter-defendant CSPC Limited is a Hong Kong company, while plaintiff CSPC Dophen is a New Jersey Corporation. (
Plaintiff's motion to dismiss argues that these amended counterclaims are "nearly identical" and both fail to satisfy the specificity required by Rule 9(b). (Pl.'s MTD (ECF No. 70) at 13-14.) Rule 9(b) requires that "[i]n alleging fraud or mistake, a party must state with particularity the circumstances constituting fraud or mistake. Malice, intent, knowledge, and other conditions of a person's mind may be alleged generally."
"Rule 9(b) serves not only to give notice to defendants of the specific fraudulent conduct against which they must defend, but also `to deter the filing of complaints as a pretext for the discovery of unknown wrongs, to protect [defendants] from the harm that comes from being subject to fraud charges, and to prohibit plaintiffs from unilaterally imposing upon the court, the parties and society enormous social and economic costs absent some factual basis.'"
Circumstances that must be stated with particularity pursuant to Rule 9(b) include the "time, place, and specific content of the false representations as well as the identities of the parties to the misrepresentations."
Here, these amended counterclaims are asserted against "all Counter-Defendants." (Def.'s Am. CC (ECF No. 39) at 17-18.) And the allegations offered in support of these claims assert simply that the "Counter-Defendants made numerous representations" to Dr. Hu "concerning: (a) financial funding of the joint venture; (b) issuance of shares in CSPC Limited; (c) intent to market the products developed; and the (sic) (d) the consent to the formation of Dophen Biomed, Ind." (
Accordingly, plaintiff's motion to dismiss these counterclaims is granted. Defendant is also granted leave to amend these counterclaims.
Plaintiff next seeks dismissal of defendant's tenth amended counterclaim for declaratory relief. (Pl.'s MTD (ECF No. 70) at 22-24.) A claim for
Here, defendant has asserted several counterclaims against plaintiff for money and for which plaintiff has not sought dismissal. Specifically, even after granting plaintiff's motion to dismiss, defendant's counterclaims for breach of contract, failure to pay wages and other benefits, breach of fiduciary duty, and violation of California Business & Professions Code § 17200, et seq., will remain.
Moreover, it appears that the allegations of defendant's counterclaim for declaratory relief concern past wrongs such as whether Dr. Hu obtained an ownership in CSPC Limited, whether Dr. Hu had a right to form Dophen Biomed, Inc., and whether the parties formed a joint venture. (Def.'s CC (ECF No. 39) at 21-22.) As noted above, "declaratory relief is intended to offer guidance in shaping future conduct so as to avoid breach of a party's obligations."
Accordingly, plaintiff's motion to dismiss this counterclaim will also be granted. Defendant, however, is also granted leave to amend this counterclaim.
Plaintiff seeks to strike defendant's prayer for punitive damages as it pertains to the counterclaims for breach of contract, failure to pay wages and other benefits, and violation of Business & Professions Code § 17200, et. seq. (Pl.'s MTD (ECF No. 70) at 25.) Plaintiff's motion must be granted as defendant cannot obtain punitive damages pursuant to any of those claims.
Accordingly, plaintiff's motion to strike this portion of defendant's amended counterclaim is granted and defendant is also granted leave to amend.
For the reasons stated above, plaintiff's motion to dismiss will be granted. Accordingly, the following counterclaims found in the amended counterclaim will be dismissed—the third cause of action for defamation, fifth cause of action for conversion, seventh cause of action for fraud and intentional misrepresentation, eighth cause of action for negligent misrepresentation, tenth cause of action for declaratory relief, and eleventh cause of action for money had and received. Additionally, the amended counterclaim's prayer for punitive damages as it pertains to the first cause of action for breach of contract, second cause of action for failure to pay wages and other benefits, and ninth cause of action for violation of Business & Professions Code § 17200, et. seq. will be stricken.
The undersigned has carefully considered whether Dr. Hu could further amend the counterclaim to correct the defects noted above. "Valid reasons for denying leave to amend include undue delay, bad faith, prejudice, and futility."
However, when evaluating the failure to state a claim, the pleading of a pro se party may be dismissed "only where `it appears beyond doubt that the [party] can prove no set of facts in support of his claim which would entitle him to relief.'"
Here, the undersigned cannot yet say that granting Dr. Hu further leave to amend would be futile. Dr. Hu will, therefore, be granted leave to file a second amended counterclaim. Defendant is cautioned, however, that if defendant elects to file a second amended counterclaim "the tenet that a court must accept as true all of the allegations contained in a [pleading] is inapplicable to legal conclusions. Threadbare recitals of the elements of a cause of action, supported by mere conclusory statements, do not suffice."
Defendant is also reminded that the court cannot refer to a prior pleading in order to make an amended pleading complete. Local Rule 220 requires that any amended counterclaim be complete in itself without reference to prior pleadings. The second amended counterclaim will supersede the amended counterclaim, just as the amended counterclaim superseded the original counterclaim.
Counter-defendant CSPC Pharmaceutical Group Limited ("CSPC Limited") and counter-defendants Yingui Li, Jinxu Wang, Jumin Sun, and Dongchen Cai ("individual counter-defendants"), move to dismiss counterclaimant Dr. Hu's amended counterclaim based on a lack of personal jurisdiction pursuant to Rule 12(b)(2). (ECF Nos. 95 & 96.) Dr. Hu bears the burden of establishing that jurisdiction is proper, although he need only make a prima facie showing of jurisdictional facts to withstand the motion to dismiss.
"Federal courts ordinarily follow state law in determining the bounds of their jurisdiction over persons."
Federal courts may exercise either general or specific personal jurisdiction. General personal jurisdiction is found where the nonresident defendant's "affiliations with the State are so `continuous and systematic' as to render them essentially at home in the forum State."
Specific personal jurisdiction is found where "[a] nonresident defendant's discrete, isolated contacts with the forum support jurisdiction on a cause of action arising directly out of its forum contacts[.]"
A three-part test has been developed by the Ninth Circuit to analyze an assertion of specific personal jurisdiction:
Here, Dr. Hu's amended counterclaim fails to allege any jurisdictional facts that could support either general or specific personal jurisdiction. To the contrary, the amended counterclaim alleges that counter-defendant CSPC Limited "is a foreign Corporation organized under the laws of Hong Kong, with its principal place of business" in Hong Kong." (Def.'s Am. CC (ECF No. 39) at 2-3.) And each of the individual counter-defendants allegedly reside in China. (
Moreover, the amended counterclaims asserted against either counter-defendant CSPC Limited or the individual counter-defendants are defamation, breach of fiduciary duty, conversion, fraud, negligent misrepresentation, violation of California Business & Professions Code § 17200, declaratory relief, and money had and received. (Def.'s Am. CC (ECF No. 39) at 10-22.) The amended counterclaim, however, fails to explain how any of these claims arise out of or relate to the counter-defendants' forum-related activities.
Dr. Hu's opposition to counter-defendant CSPC Limited's motion to dismiss relies heavily on the argument that counter-defendant CSPC Limited is the parent company of plaintiff CSPC-Dophen. (Def.'s Opp.'n (ECF No. 97) at 5.) However, "[t]he existence of a parent-subsidiary relationship is insufficient, on its own, to justify imputing one entity's contacts with a forum state to another for the purpose of establishing personal jurisdiction."
Imputed general jurisdiction over a foreign defendant that has an in-state affiliate may be found upon satisfaction of the alter ego test. "To satisfy the alter ego test, a plaintiff must make out a prima facie case (1) that there is such unity of interest and ownership that the separate personalities of the two entities no longer exist and (2) that failure to disregard their separate identities would result in fraud or injustice."
"The `unity of interest and ownership' prong of this test requires `a showing that the parent controls the subsidiary to such a degree as to render the latter the mere instrumentality of the former.'"
Dr. Hu's opposition to the individual counter-defendants' motion to dismiss relies on the argument that that three of those counter-defendants were employees of plaintiff CSPC-Dophen. (Def.'s Opp.'n (ECF No. 99) at 2.) However, "[u]nder the fiduciary shield doctrine, a person's mere association with a corporation that causes injury in the forum state is not sufficient in itself to permit that forum to assert jurisdiction over the person. Rather, there must be a reason for the court to disregard the corporate form."
Here, the amend counterclaim's allegations fail to provide sufficient facts with respect to each counter-defendant's contacts with California. Accordingly, counter-defendants' motions to dismiss for lack of personal jurisdiction will be granted. However, because the undersigned cannot say that granting Dr. Hu leave to amend would be futile, Dr. Hu will also be granted leave to amend his counterclaims to address personal jurisdiction.
Counter defendants also seeks dismissal due to insufficient service of process. (ECF Nos. 95 & 96.) Pursuant to Rule 12(b)(5), a defendant may move to dismiss the action where the plaintiff has failed to effect proper service of process in compliance with the requirements set forth under Rule 4 of the Federal Rules of Civil Procedure. Fed. R. Civ. P. 12(b)(5). If the court determines that the plaintiff has not properly served the defendant in accordance with Rule 4, the court has discretion to either dismiss the action for failure to effect proper service, or instead merely quash the ineffective service that has been made on the defendant in order to provide the plaintiff with the opportunity to properly serve the defendant.
"[S]ervice of summons is the procedure by which a court having venue and jurisdiction of the subject matter of the suit asserts jurisdiction over the person of the party served."
Moreover, although a defendant's appearance to attack sufficiency of service is an admission that the defendant has actual knowledge of the lawsuit, actual knowledge does not substitute for proper service of process.
When a defendant challenges service, the plaintiff bears the burden of establishing the validity of service as governed by Rule 4 of the Federal Rules of Civil Procedure.
Here, Dr. Hu attempted service of process on counter-defendant CSPC Limited by way of personal service. (ECF No. 86-1.) And service of process on the individual counter-defendants was attempted via email. (ECF No. 86-2.) Such methods of service are not permissible here.
Accordingly, defendants' motion to dismiss for insufficient service of process will also be granted. However, the court finds good cause to grant Dr. Hu leave to effect proper service.
Accordingly, IT IS HEREBY ORDERED that:
1. Defendant's July 13, 2018 motion to disqualify (ECF No. 84) is denied;
2. Plaintiff's May 30, 2018 partial motion to dismiss (ECF No. 70) is granted;
3. Counter-Defendant CSPC Limited's August 13, 2018 motion to dismiss (ECF No. 95) is granted;
4. Counter-defendants Yingui Li, Jinxu Wang, Jumin Sun, and Dongchen Cai's August 16, 2018 motion to dismiss (ECF No. 96) is granted;
5. The amended counterclaims of defamation, conversion, fraud and intentional misrepresentation, negligent misrepresentation, declaratory relief, and money had and received are dismissed against plaintiff CSPC Dophen;
6. The amended counterclaims' prayer for punitive damages with respect to the counterclaims of breach of contract, failure to pay wages and other benefits, and violation of California Business & Professions Code § 17200, is stricken as to plaintiff CSPC Dophen;
7. Defendant is granted leave to file a second amended counterclaim and to effect proper service within twenty-eight days of the date of this order. However, defendant is not required to file a second amended counterclaim, or attempt to effect proper service, and may stand on the remaining claims of the amended counterclaim—breach of contract, failure to pay wages and other benefits, breach of fiduciary duty, and violation of California Business & Professions Code § 17200—asserted against plaintiff CSPC Dophen. In the event that defendant does not file a timely second amended counterclaim, the court will construe defendant's election as consent to the dismissal of all other counter-defendants and all other claims without prejudice.